Literature DB >> 34369909

Trends in HIV Care Outcomes Among Adults and Adolescents-33 Jurisdictions, United States, 2014-2018.

André Dailey1, Anna Satcher Johnson, Xiaohong Hu, Zanetta Gant, Shacara Johnson Lyons, William Adih.   

Abstract

BACKGROUND: With significant improvements in the diagnosis and treatment of HIV, the number of people with HIV in the United States steadily increases. Monitoring trends in HIV-related care outcomes is needed to inform programs aimed at reducing new HIV infections in the United States.
SETTING: The setting is 33 United States jurisdictions that had mandatory and complete reporting of all levels of CD4 and viral load test results for each year during 2014-2018.
METHODS: Estimated annual percentage change and 95% confidence intervals were calculated to assess trends in stage of disease at time of diagnosis, linkage to HIV medical care within 1 month of HIV diagnosis, and viral suppression within 6 months after HIV diagnosis. Differences in percentages were analyzed by sex, age, race/ethnicity, and transmission category for persons with HIV diagnosed from 2014 to 2018.
RESULTS: Among 133,477 persons with HIV diagnosed during 2014-2018, the percentage of persons who received a diagnosis classified as stage 0 increased 13.7%, stages 1-2 (early infections) increased 2.9%, stage 3 (AIDS) declined 1.5%, linkage to HIV medical care within 1 month of HIV diagnosis increased 2.3%, and viral suppression within 6 months after HIV diagnosis increased 6.5% per year, on average. Subpopulations and areas that showed the least progress were persons aged 45-54 years, American Indian/Alaska Native persons, Asian persons, Native Hawaiian/other Pacific Islander persons, and rural areas with substantial HIV prevalence, respectively.
CONCLUSIONS: New infections will continue to occur unless improvements are made in implementing the Ending the HIV Epidemic: A Plan for America strategies of diagnosing, treating, and preventing HIV infection.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 34369909      PMCID: PMC8621807          DOI: 10.1097/QAI.0000000000002778

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.771


  25 in total

1.  Broadening the focus: the need to address the social determinants of health.

Authors:  Paula A Braveman; Susan A Egerter; Robin E Mockenhaupt
Journal:  Am J Prev Med       Date:  2011-01       Impact factor: 5.043

2.  Timing of entry to care by newly diagnosed HIV cases before and after the 2010 New York State HIV testing law.

Authors:  Daniel E Gordon; Fuqin Bian; Bridget J Anderson; Lou C Smith
Journal:  J Acquir Immune Defic Syndr       Date:  2015-01-01       Impact factor: 3.731

3.  Examining barriers to care: provider and client perspectives on the stigmatization of HIV-positive Asian Americans with and without viral hepatitis co-infection.

Authors:  Laura W Russ; Ana-Claire L Meyer; Lois M Takahashi; Samuel Ou; Jason Tran; Peter Cruz; Michelle Magalong; Jury Candelario
Journal:  AIDS Care       Date:  2012-03-22

4.  Prevention of HIV-1 infection with early antiretroviral therapy.

Authors:  Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming
Journal:  N Engl J Med       Date:  2011-07-18       Impact factor: 91.245

5.  Use of Race and Ethnicity in Public Health Surveillance. Summary of the DC/ATSDR workshop. Atlanta, Georgia, March 1-2, 1993.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1993-06-25

6.  Positive Charge: Filling the Gaps in the U.S. HIV Continuum of Care.

Authors:  Cathy Maulsby; Vignetta Charles; Suzanne Kinsky; Maura Riordan; Kriti Jain; David Holtgrave
Journal:  AIDS Behav       Date:  2015-11

7.  Prevalence of undiagnosed HIV infection among persons aged ≥13 years--National HIV Surveillance System, United States, 2005-2008.

Authors:  Mi Chen; Philip H Rhodes; Irene H Hall; Peter H Kilmarx; Bernard M Branson; Linda A Valleroy
Journal:  MMWR Suppl       Date:  2012-06-15

8.  Differences in Selected HIV Care Continuum Outcomes Among People Residing in Rural, Urban, and Metropolitan Areas-28 US Jurisdictions.

Authors:  John A Nelson; Anna Kinder; Anna Satcher Johnson; H Irene Hall; Xiaohong Hu; Donna Sweet; Alyssa Guido; Harold Katner; Jennifer Janelle; Maribel Gonzalez; Natalia Martínez Paz; Charlotte Ledonne; Jason Henry; Theresa Bramel; Jeanne Harris
Journal:  J Rural Health       Date:  2016-09-13       Impact factor: 4.333

9.  HIV Infection Linked to Injection Use of Oxymorphone in Indiana, 2014-2015.

Authors:  Philip J Peters; Pamela Pontones; Karen W Hoover; Monita R Patel; Romeo R Galang; Jessica Shields; Sara J Blosser; Michael W Spiller; Brittany Combs; William M Switzer; Caitlin Conrad; Jessica Gentry; Yury Khudyakov; Dorothy Waterhouse; S Michele Owen; Erika Chapman; Jeremy C Roseberry; Veronica McCants; Paul J Weidle; Dita Broz; Taraz Samandari; Jonathan Mermin; Jennifer Walthall; John T Brooks; Joan M Duwve
Journal:  N Engl J Med       Date:  2016-07-21       Impact factor: 91.245

10.  Community Outbreak of HIV Infection Linked to Injection Drug Use of Oxymorphone--Indiana, 2015.

Authors:  Caitlin Conrad; Heather M Bradley; Dita Broz; Swamy Buddha; Erika L Chapman; Romeo R Galang; Daniel Hillman; John Hon; Karen W Hoover; Monita R Patel; Andrea Perez; Philip J Peters; Pam Pontones; Jeremy C Roseberry; Michelle Sandoval; Jessica Shields; Jennifer Walthall; Dorothy Waterhouse; Paul J Weidle; Hsiu Wu; Joan M Duwve
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-05-01       Impact factor: 17.586

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.